Article By:
The Life Sciences Report
Thursday, July 9, 2015 8:45 AM EDT
Jason Napodano, CFA, of Zacks Investment Research details the upside for small-cap biotech names that he believes will be huge gainers for investor portfolios.
In this article: BCLI, CUR, CYNAF, GSK, NVIV Also: NBI, ACOR, AMGN, BIIB, BLUE, CELG, DEPO, GILD, IBB, JUNO, KITE, LLY, MD, PFE, RVXCF, D-STEM (DEFUNCT), SYK